Hadassah

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Monday, May 7 2018

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

PLX-R18’s initial critical preclinical animal studies that set the basis for this treatment were performed by Prof. Gorodetsky at Hadassah. Further preclinical trials conducted by the U.S. National Institutes of Health, Prof. Gorodetsky at Hadassah, researchers at the Charité University Hospital in Berlin, and other prominent research institutions have shown that PLX-R18 cells secrete a range of specific proteins that salvage and trigger the regeneration of bone marrow hematopoietic (blood-producing) cells. In this way, they efficiently support the indirect recovery and regeneration of the blood system.

Read more about the development and milestones of PLX-R18 at:
http://www.hadassah.org/news-stories/placental-stem-cell-therapy-fda.html

Dr. Gorodetsky’s family has been intertwined with Hadassah for 70 years.  Listen as he traces this connection back to 1948.

Learn more about the Hadassah Medical Organization.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Mar 22 2019

On World TB Day, March 24, Hadassah Celebrates Its Success Treating TB

Hadassah has been working on reducing the incidence of tuberculosis for nearly 100 years.

READ MORE ›
alt_text

Thursday, Mar 21 2019

Large Multinational Study Reveals Benefits of Dapagliflozin for Treatment of Diabetes

With 450 million adults worldwide suffering from diabetes today and an increase to more than 640 million expected by 2040, the need for a safe and effective treatment is ever more compelling.

READ MORE ›
alt_text

Tuesday, Mar 19 2019

Hadassah Genetic Research Demystifies Causes of Day Blindness in Families

Fifteen years ago, Prof. Dror Sharon joined the Hadassah Medical Organization’s Center for Retinal and Macular Degeneration to study the genetics of eye disease.

READ MORE ›
alt_text

Wednesday, Mar 13 2019

Saving Lives, Changing Lives at Hadassah-Neurim Youth Aliyah Village

Henrietta Szold was the mother of Youth Aliyah. The first young Jews who came on their own in the mid-1930s were fleeing Hitler. Many never saw their parents again, and they called her Ima. She met their boats, welcomed them, and became their staunch advocate in the no-frills pre-state Israel.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More